Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
about
Use of antidepressants during pregnancy: a better choice for some.The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review.First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review.Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making.
P2860
Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
@en
Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
@nl
type
label
Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
@en
Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
@nl
prefLabel
Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
@en
Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
@nl
P2093
P2860
P1476
Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.
@en
P2093
Alessandra Marini
Cesario Bellantuono
Chiara Lucarelli
P2860
P304
P356
10.1007/S40261-013-0112-Y
P577
2013-09-01T00:00:00Z